We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo

News  
Published: June 25, 2008
 
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above. ✖

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy
Read time: Less than a minute

GeneGo, Inc. has announced that VTT has licensed MetaCore™. VTT develops high-throughput methods for cancer research, drug discovery and diagnostics. The focus is in investigating mechanisms of cancer development and progression, identification of therapeutic targets and exploration of the mechanism of action of anti-cancer compounds.

VTT will utilize MetaCore and MetaDrug in high-throughput compound screening, RNA interference experiments, cell biology and bioinformatics projects to identify pathways and networks important in translational cancer research.

There are 85 researchers and staff members working in VTT's Medical Biotechnology Knowledge Centre in Turku. The research is funded by the European Commission and the Academy of Finland.

VTT accommodates two EU Marie Curie Centre of Excellence teams and coordinates the Academy of Finland Centre of Excellence for translational genome-wide biology

Related Topic Pages
High-Throughput Screening
Screening Strategies in Drug Discovery
Advertisement
Advertisement
Advertisement
Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter